148 related articles for article (PubMed ID: 37701564)
1. Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis.
Ouyang J; Wang Z; Yuan K; Yang Y; Zhou Y; Li Q; Yang N; Zhao H; Zhao H; Zhou J
J Hepatocell Carcinoma; 2023; 10():1465-1477. PubMed ID: 37701564
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.
Chen W; Hu S; Liu Z; Sun Y; Wu J; Shen S; Peng Z
Hepatol Int; 2023 Apr; 17(2):406-416. PubMed ID: 36645648
[TBL] [Abstract][Full Text] [Related]
3. Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis.
Danzeng A; Guo L; Yang ZH; He ZW; Zeng CL; Ciren P; Lan RH; Jiang XW; Wang C; Zhang BH
J Gastrointest Surg; 2024 May; ():. PubMed ID: 38723996
[TBL] [Abstract][Full Text] [Related]
4. Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy.
Dai MG; Liu SY; Lu WF; Liang L; Ye B
Clin Med Insights Oncol; 2023; 17():11795549231180351. PubMed ID: 37342206
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit from adjuvant TACE combined with Lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.
Liang L; Xu ZD; Lu WF; Du CF; Gao ZY; Huang XK; Wang KD; Ye TW; Dai MG; Liu SY; Shen GL; Liu JW; Zhang CW; Huang DS
Asian J Surg; 2024 May; ():. PubMed ID: 38724372
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients.
Zhang WQ; Zhang Q; Tan L; Guan ZF; Tian F; Tang HT; He K; Chen WQ
Front Oncol; 2023; 13():1289916. PubMed ID: 38179173
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy.
Wei MC; Zhang YJ; Chen MS; Chen Y; Lau WY; Peng ZW
Front Oncol; 2022; 12():868429. PubMed ID: 35814378
[TBL] [Abstract][Full Text] [Related]
9. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.
Li J; Wang WQ; Zhu RH; Lv X; Wang JL; Liang BY; Zhang EL; Huang ZY
Front Immunol; 2023; 14():1202039. PubMed ID: 37359534
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study.
Cai J; Zhao J; Liu D; Xie H; Qi H; Ma J; Sun Z; Zhao H
Front Oncol; 2021; 11():781029. PubMed ID: 34926296
[TBL] [Abstract][Full Text] [Related]
11. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion.
Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S
Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus-related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection.
Bai S; Hu L; Liu J; Sun M; Sun Y; Xue F
Front Oncol; 2022; 12():919824. PubMed ID: 35898866
[TBL] [Abstract][Full Text] [Related]
14. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
15. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
16. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.
Gou XX; Shi HY; Li C; Chen ZL; Ouyang W; Sun LY; Diao YK; Wang MD; Yao LQ; Gu LH; Pawlik TM; Lau WY; Shen F; Xue J; Yang T
Int J Radiat Oncol Biol Phys; 2022 Oct; 114(2):238-249. PubMed ID: 35643251
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience.
Zhang S; Yang G; Song R; Wang W; Meng F; Yin D; Wang J; Zhang S; Cai W; Liu Y; Luo D; Wang J; Liu L
Ther Adv Med Oncol; 2024; 16():17588359241258394. PubMed ID: 38882444
[TBL] [Abstract][Full Text] [Related]
18. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching.
Wu Z; Tang H; Wang L; Jin X; Lei Z; Yang P; Zhou J
BMC Surg; 2022 Mar; 22(1):103. PubMed ID: 35313836
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion.
Wang L; Wang W; Yao X; Rong W; Wu F; Chen B; Liu M; Lin S; Liu Y; Wu J
Oncotarget; 2017 Oct; 8(45):79971-79981. PubMed ID: 29108379
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.
Wu Z; Cui L; Qian J; Luo L; Tu S; Cheng F; Yuan L; Zhang W; Lin W; Tang H; Li X; Li H; Zhang Y; Zhu J; Li Y; Xiong Y; Hu Z; Peng P; He Y; Liu L; He K; Shen W
BMC Cancer; 2023 Apr; 23(1):325. PubMed ID: 37029339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
